What is Zacks Small Cap’s Estimate for RVPH FY2024 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities researchers at Zacks Small Cap lifted their FY2024 EPS estimates for Reviva Pharmaceuticals in a research report issued on Monday, December 23rd. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($0.97) per share for the year, up from their prior forecast of ($0.98). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.22) EPS.

Separately, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH stock opened at $1.78 on Wednesday. Reviva Pharmaceuticals has a 1 year low of $0.60 and a 1 year high of $5.67. The firm has a market cap of $59.52 million, a price-to-earnings ratio of -1.60 and a beta of -0.02. The stock’s 50-day moving average is $1.40 and its two-hundred day moving average is $1.25.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.